| pubmed-article:11033441 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11033441 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:11033441 | lifeskim:mentions | umls-concept:C0029433 | lld:lifeskim |
| pubmed-article:11033441 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:11033441 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:11033441 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:11033441 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:11033441 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:11033441 | lifeskim:mentions | umls-concept:C1956225 | lld:lifeskim |
| pubmed-article:11033441 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11033441 | pubmed:dateCreated | 2000-11-21 | lld:pubmed |
| pubmed-article:11033441 | pubmed:abstractText | In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs. Daily subcutaneous administration of PTH(1-34) for 15 days caused a dose-dependent increase in the serum osteocalcin level and bone extract alkaline phosphatase activity, markers of bone formation. PTH(2-34) was much less potent, whereas PTH(1-31) was equipotent in stimulating bone formation parameters in mice. PTH(1-34) caused significant increases in serum calcium (after 4 h) and tartrate-resistant acid phosphatase activity in bone extract (after 4 h), whereas PTH(2-34) and PTH(1-31) were less potent. Because PTH(1-31) caused a smaller increase in bone resorption parameters compared to PTH(1-34), despite similar effects on bone formation parameters, we evaluated the long-term anabolic effects of PTH(1-31) and PTH(1-34) in mice. Weekly evaluations of serum osteocalcin levels demonstrated that daily injections of PTH(1-34) and PTH(1-31) at 80 microg/kg body weight increased serum osteocalcin levels within 1 week of the start of treatment, which were maintained during the entire 22 week treatment. Assessment of bone density at the end of the treatment period with peripheral quantitated computed tomography (pQCT) revealed that PTH(1-34) caused a significantly greater increase in femoral bone density compared to PTH(1-31) at the middiaphysis (18% vs. 9% over vehicle control; p < 0.001). Both PTH(1-34) and PTH(1-31) increased periosteal circumference compared to vehicle (p < 0.01) without a significant difference between the two treatments. In contrast, PTH(1-34) caused a significantly greater reduction in endosteal circumference than PTH(1-31) (p < 0.001). Both analogs significantly increased maximum load and area of moment of inertia over the vehicle group. In conclusion, our findings suggest that PTH(1-34) and PTH(1-31) may exhibit different anabolic effects at the periosteum vs. endosteum in the long bones of mice. | lld:pubmed |
| pubmed-article:11033441 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033441 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033441 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11033441 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033441 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11033441 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033441 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033441 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11033441 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11033441 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11033441 | pubmed:issn | 8756-3282 | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:KodamaYY | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:MohanSS | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:BaylinkD JDJ | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:SrivastavaA... | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:WergedalJ EJE | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:BeamerW GWG | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:ZhangCC | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:KutilekSS | lld:pubmed |
| pubmed-article:11033441 | pubmed:author | pubmed-author:ShenH GHG | lld:pubmed |
| pubmed-article:11033441 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11033441 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:11033441 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11033441 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11033441 | pubmed:pagination | 471-8 | lld:pubmed |
| pubmed-article:11033441 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11033441 | pubmed:meshHeading | pubmed-meshheading:11033441... | lld:pubmed |
| pubmed-article:11033441 | pubmed:meshHeading | pubmed-meshheading:11033441... | lld:pubmed |
| pubmed-article:11033441 | pubmed:meshHeading | pubmed-meshheading:11033441... | lld:pubmed |
| pubmed-article:11033441 | pubmed:meshHeading | pubmed-meshheading:11033441... | lld:pubmed |
| pubmed-article:11033441 | pubmed:meshHeading | pubmed-meshheading:11033441... | lld:pubmed |
| pubmed-article:11033441 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11033441 | pubmed:articleTitle | Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. | lld:pubmed |
| pubmed-article:11033441 | pubmed:affiliation | Musculoskeletal Disease Center, Jerry L. Pettis VA Medical Center, Loma Linda, CA 92357, USA. mohans@lom.med.va.gov | lld:pubmed |
| pubmed-article:11033441 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11033441 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11033441 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11033441 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:11033441 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033441 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033441 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033441 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033441 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033441 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033441 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033441 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11033441 | lld:pubmed |
